In developing countries, the cost of antihypertensive medications is one of the principal limiting factors when trying to treat patients with high blood pressure. To determine the changes in cost (in US dollars) of these medications and in the percentage of the minimum wage needed to purchase them, two cost studies (1990 and 1996) The comparison of these two cost studies (1990 and 1996) shows why Mexico's population is finding it more difficult to purchase antihypertensive medications. Higher costs and reduced purchasing power seem to be the two principal factors causing this. This is probably affecting the population's health, as it is more difficult to control high blood pressure without proper treatment. Am J Hypertens 1998;11:487-493
T he majority of developing countries (Mexico included) are suffering an epidemiological transition; cardiovascular illnesses are beginning to occupy the first place in these populations' morbidity and mortality.
1,2 Due to this, today the principal challenge for these countries is the control and prevention of chronic illnesses, cardiovascular diseases among them, using a series of very limited resources. 3 Part of the cardiovascular complications caused by high blood pressure can be prevented with pharmacological treatments. 4 This can be achieved by using the old antihypertensives (␤-blocking agents, reserpine, and diuretics), which have a clear history of reducing cardiovascular morbidity and mortality. 4, 5 New medications, such as angiotensin converting enzyme inhibitors and calcium channel blockers, are also available to treat high blood pressure, but they are much more expensive. The efficacies of these newer agents have only been judged against surrogate end points, and have not been shown in prospective studies to reduce mortality.
Several studies have shown that the cost of antihypertensive medications is a limiting factor for low income patients to continue a treatment. [5] [6] [7] [8] In the last two decades the socioeconomic environment of Mexico has been characterized by a progressive deterioration in wages and purchasing power. 9 Added to this is the fact that 40% of Mexico's population does not have access to health care that includes the cost of medications. 10 In 1990 we did a study in Mexico to determine the costs of the most commonly used antihypertensive medications and the percentage of the minimum wage in effect at the time needed to purchase these medications, calculated on a monthly basis.
11
In 1996, almost 2 years after the worst economic crisis in Mexico's history, we considered it a priority to determine the changes in costs of antihypertensive medications, and the change in the percentage of the minimum wage necessary to purchase these medications, using our 1990 study for comparison.
We also wanted to include the new long-acting antihypertensive medications in our cost survey; the majority of them were not available in Mexico at the time of our first survey in 1990.
To complete our new survey, we decided to calculate the number needed to treat (NNT) with antihypertensive medications to reduce cerebrovascular events, and to include the cost of basic medical consultation and lab studies needed to treat a patient with high blood pressure, to determine the cost of patient care and medication comparison, and the impact of patient care plus medication on the minimum wage.
MATERIALS AND METHODS
In 1990 we published a study in Mexico of the costs of the most commonly used antihypertensive medications in the treatment of high blood pressure 11 ; the cost of the medications was also compared percentwise to the minimum wage in effect at the time, on a monthly basis. 11 The same procedure was repeated in the 1996 study, and was as follows. The daily dosage of each antihypertensive medication was the one recommended by U.S. Joint National Committee for the Detection, Evaluation and Treatment of High Blood Pressure (1988 version) . 12 The monthly and yearly dosage was calculated, and its cost was determined. The cost was then converted into US dollars, using the exchange rate in effect at the time of the study.
When determining the cost of each antihypertensive medication, the official maximum price (fixed by the Mexican federal government) of the least expensive brand name on the market was used. It should be mentioned that no medication in Mexico is sold to the public under generic names. Only the public health sector uses generic medications, and they are available only to them.
To get an idea of the population's purchasing power, we calculated the percentage of the minimum wage necessary to purchase the various antihypertensive medications. The wages and exchange rates were the ones in effect at the time of each study. As with the price of medications, the minimum wage is also established by the federal government.
In addition, the new long-acting antihypertensive medications were subjected to a cost analysis for the first time in Mexico. For this part of the study, we chose the most commonly used medications on the market, and the dosages were the ones most commonly used in daily practice. Again, the prices of the medications and the minimum wage were the ones officially set by the Mexican government at the time of the study. The exchange rate into US dollars was also the one in effect at the time of the study.
The cost of three medical consultations, two laboratory evaluations (complete blood count, urea, creatinine, seric sodium, potassium and total cholesterol, urinalysis, and electrocardiogram) were determined. The prices used were the ones charged at the Nuevo Civil Hospital of Guadalajara, Jalisco, Mexico, at the time of the study. (This institution offers care to low income patients who do not have the total medical coverage offered by the Mexican Social Security Institute; their prices are the lowest on the market.) The costs were then converted into US dollars at the exchange rate in effect at the time of the study, and them compared with the costs of antihypertensive medications (the most economical one of each group) and the minimum wage.
To have a better idea of what the cost of pharmacological treatment for hypertension can represent in a developing country, the NNT in order to prevent a cerebrovascular event was calculated. The information reported by the Isolated Systolic Hypertension in the Elderly Study, 13 for the group 60 to 69 years of age was used, and whose absolute risk was 0.13 after 5 years of treatment.
A representative medication was chosen from each of the four groups, and the annual cost of each of them was multiplied by the 17 patients who should be treated in order to prevent a cerebrovascular event, and then multiplied by the 5 years of treatment.
RESULTS
The daily dosage, monthly and yearly costs of the medications in 1990 and 1996, and the variation in cost between 1990 and 1996 are presented in Table 1 . Hydrochlorothiazide was the only medication that cost less in 1996 than in 1990. Surprisingly, atenolol and clonidine, which also have been on the market for a number of years, underwent large price increases.
The daily dosage, the percentage of the minimum wage necessary to purchase the antihypertensive Table 2 . Again, only hydrochlorothiazide held its ground against the economic tide, the percentage of the minimum wage remaining stable between the two periods. On the other hand, angiotensin converting enzyme inhibitors all cost Ͼ 40% of the minimum wage. The monthly and annual costs of newer antihypertensive medications available in Mexico are presented in Table 3 . The annual costs of the different antihypertensive medication groups, medical consultations, and laboratory tests, and percentwise analysis of their costs are presented in Table 4 . Also included is an analysis of the minimum wage necessary for this patient care, diagnosis, and treatment. Again, diuretics were the most economical form of treatment. The cost of diuretics was also less than the cost of medical consultation and diagnostic tests, that is, only 18.6% of the total patient treatment cost. Compared against the monthly minimum wage, the total patient treatment cost with diuretics was 5.8% of this. At the other extreme, the angiotensin converting enzyme inhibitors represented 89.5% of the total patient treatment cost, and the total patient treatment cost with angiotensin converting enzyme inhibitors represented 45.4% of the monthly minimum wage. Table 5 shows the results of the estimated cost of the antihypertensive treatment in order to prevent a cerebrovascular event, according to the NNT. The enalapril based treatment was 39 times more costly than the thiazide based treatment.
DISCUSSION
As in other developing countries in the last few years, Mexico has seen cardiovascular illnesses increase to 22 become the top causes of death. 10 High blood pressure is responsible for a very important percentage of this mortality. 10, 14 Various clinical studies have shown that pharmacological treatment of high blood pressure significantly reduces cardiovascular morbidity and mortality. 4, [13] [14] [15] During the next several years, health authorities in developing countries are going to have to face the challenge of preventing and treating cardiovascular illnesses with very limited resources. 2, 3, 14 This means that these few resources are going to have to be used in an extremely efficient manner.
One crucial aspect for the success of any high blood pressure control program is the availability of antihypertensive medications. 16 Almost 40% of the Mexican population does not have access to health institutions that provide this type of medication. 10 This part of the population with high blood pressure must pay for treatment and medications out of their own salaries or wages.
Studies done in developed countries by Rocella, 7 McMahon et al, 17 Calvo-Vargas and Valdiva, 18 and WHL 16 have shown that for low income patients, the cost of antihypertensive medications is one of the principal factors limiting their ability to continue the treatment.
The selection of a pharmacological treatment for high blood pressure should be determined by the medication's effectiveness in reducing mortality. Diuretics, reserpine, and ␤-blocking agents all have been shown to reduce the morbidity and mortality related with hypertension. 4, 15, 19 Calcium channel blockers and angiotensin converting enzyme inhibitors are effective for controlling high blood pressure, 4 but their cost is much greater than that of the older medications (Table 1) ; their efficacy has been judged only against surrogate end points; and they have not been shown in prospective studies to reduce mortality.
According to the results of this investigation, a Mexican laborer had to work 0.23 day in 1996 in order to pay for a month's worth of antihypertensive treatment based on diuretics. If that person had been treated with an angiotensin converting enzyme inhibitor, he would have had to work for almost 15 days to pay for this type of medication (Table 1) .
Upon analyzing the evolution in the costs of antihypertensive medications between 1990 and 1996, two social factors seem to be affecting the cost of medications and the population's capacity to purchase them. The first is the loss of the purchasing power of wages; a higher percentage of wages must be spent to buy the same medications. The second factor is the price increase in medications, some costing two to three times more than in 1990. The price increase in US dollars seems to be higher than the inflation rate in Mexico for the same period. 9 The increase in the cost of medications and the loss of purchasing power are caused in principal by the Mexican government's political policies; in the last few years its neoliberal system has been characterized by a fall in general productivity and a notable increase in unemployment. 9 An interesting fact is that Mexico has been part the Free Trade Agreement with the US and Canada since 1994. 10 When the prices of antihypertensive medications are compared with those in the United States, it is apparent that the costs in Mexico are getting closer to the US prices, especially in the case of antihypertensive medications. 20 As is the case in developing countries, the annual cost of caring for high blood pressure patients is composed principally by the cost of medications, 16 with the exception of those patients who receive treatments based on diuretics (Table 4 ). This is due to the fact that government run health facilities have considerably lowered the cost of patient care. The inverse happens in developed countries, where patient care is much more expensive than medications. 20 The World Bank, among other institutions, maintains that in developing countries it is not possible to control high blood pressure with medications due to their high cost.
14 They suggest that the only way to control the illness is by using more nonpharmacological methods. Unfortunately, these methods fail in a high percentage of patients, making it necessary to use some type of antihypertensive medication in almost 50% of patients in order to control their high blood pressure. 4, 16 The treatment of high blood pressure is really a preventive measure. The social and individual implications of its complications, such as strokes and coronary events, are more costly and limiting than that of high blood pressure per se. The NNT reflects the differences in the costs of the medications analyzed to prevent a cerebrovascular event in a high risk group such as older people with high systolic pressure ( Table  5) . Diuretic (thiazide) based treatments are almost 40 times more economical than angiotensin converting enzyme inhibitors. This means that almost five cerebrovascular events could be prevented using thiazides instead of the other expensive medications. The new epidemiological panorama in developing countries requires, among other measures, control over high blood pressure in order to lower cardiovascular mortality. 1, 3, 16 This is not possible without a social and health organization than can optimize resources. Table  6 contains a series of suggestions that can help lower the social and individual cost of the pharmacological treatment of high blood pressure, and help favor the availability of antihypertensive medications in developing countries. In first place is the education of health care personnel in the use of less costly, but just as effective, medications. 3, 19, 21 It is also necessary to work on research protocols that support the rational use of the old antihypertensive medications in large sectors of the population. 4, 16 Nevertheless, these solutions may be insufficient to solve the problem. What really is needed is a social reorganization in which the government, health institutions, pharmaceutical industry, and the general population all collaborate to define strategies and ways to improve the ability to prevent and treat cardiovascular illnesses, and to offer the best alternatives-in terms of effectiveness and cost-to improve the population's quality of life and life expectancy.
